In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxter International Inc.

https://www.baxter.com/

Latest From Baxter International Inc.

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Asia Pacific China

ASCO 2023 – Bicara Eyes Head And Neck Niche

Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.

ASCO Clinical Trials

Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future

PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.

Rare Diseases Platform Technologies

Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

China Commercial
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Other Names / Subsidiaries
    • AesRX LLC
    • Althin Medical A.B.
    • Chatham Therapeutics
    • Cheetah Medical
    • Claris Injectables Limited
    • Fusion Medical Technologies, Inc.
    • Gambro AB
    • Immuno-US
    • Prism Pharmaceuticals, Inc.
    • Renal Therapy Services
    • SIGMA International Geneeral Medical Apparatus
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Wound Care Technologies, Inc.
    • Baxter Healthcare Corporation
UsernamePublicRestriction

Register